Literature DB >> 18081909

Encephalopathy induced by levetiracetam added to valproate.

J Bauer1.   

Abstract

BACKGROUND: We report on the manifestation of a levetiracetam (LEV)-induced encephalopathy.
FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg). Frequency of generalized tonic-clonic seizures increased from one per 6 months to two per month. Neuropsychological testing showed impaired word fluency, psychomotor speed and working memory. The interictal electroencephalogram (EEG) showed a generalized slowing to 5 per second theta rhythms with bilateral generalized high-amplitude discharges. OUTCOME: Following discontinuation of LEV, EEG and neuropsychological findings improved and seizure frequency decreased.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18081909     DOI: 10.1111/j.1600-0404.2007.00974.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  4 in total

1.  Intravenous levetiracetam in critically ill children with status epilepticus or acute repetitive seizures.

Authors:  Nicholas S Abend; Heather M Monk; Daniel J Licht; Dennis J Dlugos
Journal:  Pediatr Crit Care Med       Date:  2009-07       Impact factor: 3.624

Review 2.  Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs.

Authors:  Philip N Patsalos
Journal:  Clin Pharmacokinet       Date:  2013-11       Impact factor: 6.447

3.  Levetiracetam induced encephalopathy in a patient with normal renal function: An unusual clinical encounter.

Authors:  Rajesh Verma; Rakesh Lalla; Tushar B Patil
Journal:  Ann Indian Acad Neurol       Date:  2013-10       Impact factor: 1.383

4.  Valproic Acid-induced Hyperammonemic Encephalopathy Promoted by Levetiracetam.

Authors:  Sook Young Roh; Hyun-Soon Jang; Eun Hye Jeong; Byung-Su Kim; Moon Kyung Sunwoo
Journal:  J Epilepsy Res       Date:  2014-12-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.